期刊文献+

反向线性点杂交方法检测embB基因突变在筛查结核分枝杆菌耐多药株的研究 被引量:3

Research of detecting embB mutation to screen MDR-TB by reverse line blot assay
原文传递
导出
摘要 目的:利用反向线性点杂交(Reverse Line Blot assay,RLB)技术建立检测embB基因突变筛查结核分枝杆菌耐多药株(指至少对异烟肼和利福平两种以上药物产生耐药的结核分枝杆菌,multi-drug resistant tuberculosis,MDR-TB)的方法。方法:采用比例法药敏试验检测301株结核分枝杆菌临床分离株的耐药表型,分别用测序及反向线性点杂交方法检测embB基因突变位点,并用比例法药敏试验作为表型检测对照方法,测序作为基因型检测对照方法,对RLB方法筛查耐多药株进行评价。结果:经表型药敏检测耐多药株占57.9%,非耐多药株占25.2%,全敏感株占16.9%。经测序检测94株发生embB Met306突变,其中89.4%(84/94)的突变发生在耐多药株1,0.6%为非耐多药株。Met306突变率在乙胺丁醇(Ethambutol,EMB)耐药组46.9%与乙胺丁醇敏感组47.8%间差异无统计学意义(χ2=0.01,P>0.05),而突变率在耐多药组为48.3%与非耐多药组13.2%间差异有统计学意义(χ2=48.53,P<0.01)。用反向线性点杂交检测embB基因突变位点与测序法相比敏感度为96.8%,特异度为99.0%,二者一致率达98.3%。用反向线性点杂交检测耐多药株与表型检测方法相比敏感度为48.3%,特异度为88.2%,二者一致率为60.4%。结论:反向线性点杂交方法检测em-bB基因突变可在常规检测中替代测序法快速筛查结核分枝杆菌耐多药株。 Objective:To establish a new rapid method to screen the MDR-TB by detecting the embB mutation based on RLB.Methods:Totally of 301 isolates collected in China were tested by drug sensitive test(DST) to detect the phenotype resistance.Sequencing and RLB technique were applied to detect embB mutation genotype resistance.Meanwhile,we evaluated the results of detecting embB mutation to screen MDR-TB based on RLB by phenotype method and genotype method.Results:By genotype detecting 57.9% was MDR-TB,25.2% was nonMDR-TB,16.9% was whole-susceptibility.By sequencing detecting,embB mutation were detected in 94 isolates,in which 89.4%(84/94) were MDR-TB,10.6% were non MDR-TB.The embB mutation rate between the EMB-resistance(46.9%) and EMB-susceptibility(47.8%) was no significance(χ2=0.01,P0.05).But between the MDR-TB(48.3%) and nonMDR-TB(13.2%) statistic discrepancy was tested(χ2=48.53,P0.01).Comparing with sequencing method to detect embB mutation,the sensitivity of RLB is 96.8%,the specificity is 99.0%,and the coincidence rate is 98.3%.Comparing with phenotype detecting to screen MDR-TB,the sensitivity of RLB is 48.3%,the specificity is 88.2%,and the coincidence rate is 60.4%.Conclusion:In routine method,detecting the embB mutation by RLB can replace the sequencing method to screen the MDR-TB.
出处 《中国卫生检验杂志》 CAS 2011年第3期537-539,542,共4页 Chinese Journal of Health Laboratory Technology
基金 国家自然科学基金面上项目(30771853)
关键词 结核分枝杆菌 EMBB基因 耐多药 反向线性点杂交 Mycobacterium tuberculosis embB Multi-drug resistant tuberculosis Reverse Line Blot assay
  • 相关文献

参考文献13

  • 1张楠,胡继红,万康林.乙胺丁醇耐药表型与耐药基因embB突变的关系[J].中国卫生检验杂志,2010,20(3):490-492. 被引量:11
  • 2张楠,胡继红,赵秀芹,万康林.比例法药敏试验检测乙胺丁醇耐药适合药物浓度的初步探讨[J].中国人兽共患病学报,2009,25(11):1049-1053. 被引量:4
  • 3梁建琴,吴雪琼,张俊仙,陆阳,李洪敏.寡核苷酸探针膜杂交法检测耐药结核菌[J].临床肺科杂志,2006,11(2):188-190. 被引量:4
  • 4梁建琴,吴雪琼,曹立雪,李洪敏,张俊仙.应用膜反向斑点杂交技术快速检测结核分支杆菌耐乙胺丁醇基因型的研究[J].微生物学报,2004,44(2):215-219. 被引量:10
  • 5Igor Mokrousov,Tatiana Otten,Boris Vyshnevskiy,et al.Detection ofembB306 Mutations in Ethambutol-Susceptible Clinical Isolates ofMycobacterium tuberculosis from Northwestern Russia:Implications forGenotypic Resistance Testing. Journal of Clinical Microbiology . 2002
  • 6Igor Mokrousova,,N Vijaya Bhanub,Philip N Suffys,et al.Multi-center evaluation of reverse line blot assay for detection of drug resist-ance in Mycobacterium tuberculosis clinical isolates. Journal of Mi-crobiological Methods . 2004
  • 7Ramaswamy S,Musser JM.Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tubercle and Lung Disease . 1998
  • 8Glynn J R,Whiteley J,Bifani P J,et al.Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis : a systematic review. Emerging Infectious Diseases . 2002
  • 9Sreevatsan S,Stockbauer KE,Pan X,et al.Ethambutol resistance in Mycobacterium tuberculosis: critical ro1e of embB mutations. Antimicrobial Agents and Chemotherapy . 1997
  • 10Manzour Hernando Hazbon,Miriam Bobadilla del Valle,Marta IniridaGuerrero,et al.Role ofembBcondon 306 mutations in mycobacteriumtuberculosis revisited:a novel association with broad drug resistanceand IS6110 clustering rather than ethambutol resistance. Antimicrobial Agents and Chemotherapy . 2005

二级参考文献45

  • 1Parsons L M, Salfinger M. Phenotypic and Molecular Character ization of Mycobacterium tuberculosis Isolates Resistant to both Isoniazid and Ethambutol[J]. Antimicrobial Agents and Chemo therapy, 2005,49:2218 -2225.
  • 2Sreevatsan S, Stockbauer KE, Pan X, et al. Ethambutol resist ance in Mycobacterium tuberculosis : critical role of embB mutations[J]. Antimicrobial Agents and Chemotherapy, 1997, 41 1677-1681.
  • 3Takayama K,Kilburn JO. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis[J]. Antimierob Agents Chemother, 1989,33 : 1493-1499.
  • 4Silve G, Guillen PV, Quemard, et al . Ethambutol inhibitionof glucose metabolism in myccobacteria : a possible target of the drug [J]. Antimicrob Agents Chemother, 1993, 37 : 1536-1538.
  • 5Mikusova K, Slayden RA, Besra GS, et al. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol[J]. Antimicrob Agents Chemother, 1995,39 : 2484-2489.
  • 6Heifets L B. Ethambutol MICs and MBCs for Mycobaeterium avium Complex and Mycobacterium tuberculosis[J]. Antimicrobial Agents and Chemotherapy, 1986,12, 927-932.
  • 7Hazhon M H, Miriam Bobadilla del Valle, Guerrero M I, et al. Role of embB Condon 305 Mutations in Mycobacterium tubercu losis Revisited: a Novel Association with Broad Drug Resistance and IS6110 Clustering Rather than gthambutol Resistance[J]. Antimicrobial Agents and Chemotherapy, 2005, 3794-3802.
  • 8Mokrousov I, Otten T, Vyshnevskiy B, et al. Detection of erabB306 Mutations in Ethambutol-Susceptible Clinical Isolates of Mycobacterium tuberculosis from Northwestern Russia: Implica tions for Genotypic Resistance Testing[J]. Journal of Clinical Microbiology, 2002, 3810-3813.
  • 9van Rie A, Warren R. Analysis for a limited number of gene condones can predict drug resistance of Mycobacterium tuberculosis in a high incidence community[J]. Journal of Clinical Micro biology, 2001, 39: 636-641.
  • 10Parsons L M, Salfinger M. Phenotypic and Molecular Characterization of Mycobacteriurn tuberculosis Isolates Resistant to both Isoniazid and Ethambutol[J]. Antimicrobial Agents and Chemotherapy, 2005,49: 2218 -2225.

共引文献24

同被引文献49

  • 1包洪,于庭,印璞,刘爱忠,张吉平.中国部分地区结核分支杆菌耐利福平、异烟肼和链酶素耐药基因的检测[J].中国实验诊断学,2007,11(2):232-234. 被引量:8
  • 2World Health Organization. Anti-Tuberculosis Drug Resistance inthe World. Report No. 2 Prevalence and Trends [ R ]. Geneva:WHO ,2000.
  • 3World Health Organization. Global tuberculosis control:a short up-date to the 2009 report[R]. Geneva: WHO,2009.
  • 4World Health Organization. Global tuberculosis controls urveillance,planning, financing ; WHO report 2008 [ R ] Geneva : WHO ,2008.
  • 5Wright A,Zignol M, Van-Deun A,ef al. Epidemiology of antituber-culosis drug resistance 2002-07 :an updated analysis of the GlobalProject on Anti-Tuberculosis Drug Resistance Surveillance [ J ].Lancet,2009,373(9678) :1861-1873.
  • 6中华人民共和国卫生部.全国结核病耐药性基线调查报告(2007_2008)[M].北京:人民卫生出版社,2010:30.
  • 7Rouse DA,Morris SL. Molecular mechanisms of isoniazid resistancein Mycobacterium tuberculosis and Mycobacterium bovis[ J]. InfectImmun,1995,63(4) : 1427-1433.
  • 8Ano H, Matsumoto T, Nangi T, et al. Resistance-conferring muta-tions of Mycobacterium tuberculosis strains with low level resist-ance to isoniazid[ J] . Kekkaku,2006,81 ( 12) :709-713.
  • 9Ramaswamy S,Musser JM. Molecular genetic basis ofantimicrobialagent resistance in Mycobacterium tuberculosis: 1998 update[ J].Tuber Lung Dis,1998 ,79( 1 ) :3-29.
  • 10Lee JS,Poo H, Han DP,et al. Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike pro-tein on Lactobacillus casei induces neutralizing antibodies in mice[J]. J Virol,2006,80(8) :40794087.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部